Research programme: anti-RON monoclonal antibodies - Eli Lilly

Drug Profile

Research programme: anti-RON monoclonal antibodies - Eli Lilly

Alternative Names: IMC-41A10; Ron MAb; RON-1; RON-6

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImClone Systems
  • Developer Eli Lilly
  • Class Monoclonal antibodies
  • Mechanism of Action RON protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Injection)
  • 16 Apr 2008 Preclinical pharmacodynamics data in Cancer presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)
  • 04 May 2005 Data presented at the 96th Annual Meeting of the American Association for Cancer Research (AACR-2005) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top